<DOC>
	<DOCNO>NCT01395524</DOCNO>
	<brief_summary>The purpose study evaluate effect safety NKTR-118 treatment opioid-induced constipation patient non-cancer-related pain 6-month period .</brief_summary>
	<brief_title>A 12-week Extension Phase III Study ( D3820C00004 ) Assess Effect Safety NKTR-118 Patients With Non-cancer-related Pain Opioid-induced Constipation</brief_title>
	<detailed_description />
	<mesh_term>Constipation</mesh_term>
	<mesh_term>Analgesics , Opioid</mesh_term>
	<mesh_term>Naloxegol</mesh_term>
	<criteria>Must complete 12week study D3820C00004 Visit 8 . Provision write informed consent prior studyspecific procedure . Men woman age &gt; 18 &lt; 85 year time screen visit study D3820C00004 . Continuing receive stable maintenance opioid regimen consist total daily dose 30 mg 1000 mg oral morphine , equianalgesic amount ( ) 1 opioid therapy . Willingness continue abstinence laxative bowel regimen include prune juice herbal product throughout additional 12week treatment period , use bisacodyl rescue medication bowel movement ( BM ) occur within least 72 hour last record BM . Patients receive opioid regimen treatment pain related cancer . History cancer within 5 year screen visit study D3820C00004 exception basal cell cancer squamous cell skin cancer . Medical condition treatment associate diarrhea , intermittent loose stool , constipation . Other issue relate gastrointestinal tract could impose risk patient . Pregnancy lactation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>84 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Non-Cancer-Related Pain</keyword>
	<keyword>Opioid-Induced Constipation .</keyword>
</DOC>